January 28, 2025 – The U.S. Food and Drug Administration (FDA) has officially authorized ZYN nicotine pouches, making it the first and only FDA-authorized nicotine pouch available in the United States. This decision marks a significant milestone in offering adult smokers a better alternative to traditional tobacco products.
A Science-Based Approach to Public Health
The FDA’s authorization covers all ZYN nicotine pouches currently marketed by Swedish Match in the U.S. The move aligns with the agency’s commitment to public health by supporting alternatives that reduce the risks associated with smoking and other combustible tobacco products.
ZYN’s Role in Reducing Harm from Smoking
Ali Takesh, Managing Director of Philip Morris (Pakistan) Limited, highlighted the public health benefits of ZYN.
“The FDA’s decision acknowledges the role of ZYN in helping adult users transition away from smoking and other harmful tobacco products. In Pakistan, where approximately 25.4 million people use tobacco, smoking remains the most dangerous form of nicotine consumption due to combustion,” he said.
A Model for Other Countries
Takesh emphasized that the FDA’s decision sets an example for countries like Pakistan, where smoking rates remain high.
“This decision demonstrates that nations with high tobacco use can also adopt responsible policies to market smoke-free alternatives and reduce the health burden on society,” he added.
The FDA’s authorization reinforces the importance of science-based regulations in creating safer alternatives for adult smokers while protecting public health.
